Shop Antibodies

Emapalumab Biosimilar Antibody

$205.00$2,500.00

Item Cat No.: BS0007

Antibody: Monoclonal Antibody

Concentration: 0.50 mg/ml

Application: In vitro and In vivo

Reactivity: Human

Emapalumab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human interferon-gamma (IFNγ) protein.

Emapalumab, sold under the brand name Gamifant, is an anti-interferon-gamma (IFNγ) antibody used for the treatment of hemophagocytic lymphohistiocytosis (HLH).

The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. Emapalumab acts by binding and neutralizing interferon-gamma. The specific interaction between Emapalumab and interferon-gamma produces an inhibition in the interaction between interferon-gamma and its cognate receptor on T-cells. Emapalumab can inhibit both free and IFNGR1-bound interferon-gamma as well as the interaction with IFNGR1 and IFNGR2 on the cell surface.

Host/Isotype: Human/IgG1

Class: Monoclonal

Immunogen: Human IFNγ protein

Production platform: CHO cells

Purification: Affinity chromatography

Storage buffer: PBS, pH 7.2

Storage condition: –20°C


For Research Use Only. Not for use in clinical diagnostics or therapeutics.

Additional information

Antibody Production Scale

50 ug, 250 ug, 1 mg

Conjugate

None, FITC, HRP, ADC (custom drug)

Reviews

There are no reviews yet.

Be the first to review “Emapalumab Biosimilar Antibody”

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

"The rabbit hybridoma supernatants of anti-APOBEC3 project are tested positive by ELISA, and we are very happy about it! We previously tried a company, Abclone. Their Project "A" has immune response that is <10,000 titer in antiserum, which would explain why there is no positive mAb after fusion. Their project "B" didn't have any immune response in rabbit."

Harshita B Gupta, PhD.

School of Medicine | UT Health San Antonio

Contact us for questions or custom requests!